Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 271

1.

Invasive pneumococcal disease among White Mountain Apache adults, 1991-2005.

Bliss SJ, Larzalere-Hinton F, Lacapa R, Eagle KR, Frizzell F, Parkinson A, Reid R, Craig M, Santosham M, O'Brien KL.

Arch Intern Med. 2008 Apr 14;168(7):749-55. doi: 10.1001/archinte.168.7.749.

PMID:
18413558
2.

Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.

Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, Santosham M, Craig MJ, O'Brien KL.

Clin Infect Dis. 2008 Aug 15;47(4):476-84. doi: 10.1086/590001.

PMID:
18627249
3.

Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease.

Weatherholtz R, Millar EV, Moulton LH, Reid R, Rudolph K, Santosham M, O'Brien KL.

Clin Infect Dis. 2010 May 1;50(9):1238-46. doi: 10.1086/651680.

PMID:
20367225
4.

Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults.

Singleton RJ, Butler JC, Bulkow LR, Hurlburt D, O'Brien KL, Doan W, Parkinson AJ, Hennessy TW.

Vaccine. 2007 Mar 8;25(12):2288-95. Epub 2006 Dec 11.

PMID:
17254673
5.

Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine.

Hsu K, Pelton S, Karumuri S, Heisey-Grove D, Klein J; Massachusetts Department of Public Health Epidemiologists.

Pediatr Infect Dis J. 2005 Jan;24(1):17-23.

PMID:
15665705
6.

Invasive pneumococcal disease among Navajo adults, 1989-1998.

Watt JP, O'Brien KL, Benin AL, Whitney CG, Robinson K, Parkinson AJ, Reid R, Santosham M.

Clin Infect Dis. 2004 Feb 15;38(4):496-501. Epub 2004 Jan 28.

PMID:
14765341
7.

Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003.

Greene CM, Kyaw MH, Ray SM, Schaffner W, Lynfield R, Barrett NL, Long C, Gershman K, Pilishvili T, Roberson A, Zell ER, Whitney CG, Bennett NM; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network.

Clin Infect Dis. 2006 Jul 15;43(2):141-50. Epub 2006 Jun 9.

PMID:
16779739
8.

High incidence rates of invasive pneumococcal disease in the White Mountain Apache population.

Cortese MM, Wolff M, Almeido-Hill J, Reid R, Ketcham J, Santosham M.

Arch Intern Med. 1992 Nov;152(11):2277-82.

PMID:
1444688
9.

Adults with invasive pneumococcal disease: missed opportunities for vaccination.

Kyaw MH, Greene CM, Schaffner W, Ray SM, Shapiro M, Barrett NL, Gershman K, Craig AS, Roberson A, Zell ER, Schuchat A, Bennett NM, Whitney CG; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network.

Am J Prev Med. 2006 Oct;31(4):286-92. Epub 2006 Aug 22.

PMID:
16979452
10.

Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine.

Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Mitchel E, Schaffner W, Craig AS, Edwards KM, Griffin MR.

Clin Infect Dis. 2004 Sep 1;39(5):641-8. Epub 2004 Aug 16.

PMID:
15356776
11.

Invasive pneumococcal disease in the Kimberley, 1995-2001.

Mak DB.

Aust J Rural Health. 2004 Dec;12(6):237-40.

PMID:
15615574
12.
13.

Invasive pneumococcal disease in non-Indigenous people in north Queensland, 2001-2009.

Hanna JN, Humphreys JL, Murphy DM, Smith HV.

Med J Aust. 2010 Oct 4;193(7):392-6.

PMID:
20919968
14.

The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004.

Mooney JD, Weir A, McMenamin J, Ritchie LD, Macfarlane TV, Simpson CR, Ahmed S, Robertson C, Clarke SC.

BMC Infect Dis. 2008 Apr 23;8:53. doi: 10.1186/1471-2334-8-53.

15.
16.

Advances in pneumococcal vaccines: what are the advantages for the elderly?

Vila-Córcoles A.

Drugs Aging. 2007;24(10):791-800. Review.

PMID:
17896829
17.

[Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands)].

Artiles F, Horcajada I, Cañas AM, Alamo I, Bordes A, González A, Santana M, Lafarga B.

Enferm Infecc Microbiol Clin. 2009 Jan;27(1):14-21. doi: 10.1016/j.eimc.2008.03.001. Epub 2009 Jan 9. Spanish.

PMID:
19217998
18.

Invasive pneumococcal disease: epidemiology in children and adults prior to implementation of the conjugate vaccine in the Oxfordshire region, England.

Foster D, Knox K, Walker AS, Griffiths DT, Moore H, Haworth E, Peto T, Brueggemann AB, Crook DW; Oxford Invasive Pneumococcal Surveillance Group.

J Med Microbiol. 2008 Apr;57(Pt 4):480-7. doi: 10.1099/jmm.0.47690-0.

PMID:
18349369
19.

Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000-2005.

Harboe ZB, Valentiner-Branth P, Benfield TL, Christensen JJ, Hjuler T, Kaltoft M, Krogfelt KA, Lambertsen L, Konradsen HB.

Vaccine. 2008 Jul 4;26(29-30):3765-71. doi: 10.1016/j.vaccine.2008.04.040. Epub 2008 May 5.

PMID:
18513840
20.

Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study.

Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW.

Clin Infect Dis. 2009 Jul 15;49(2):205-12. doi: 10.1086/599827.

PMID:
19508165

Supplemental Content

Support Center